$6.50
0.7212.46%
At close: Aug 20, 5:00 PM EST
$6.37
-0.13-2%
After Hours: 4:51 PM EST
Prelude Therapeutics Inc Earnings Estimates
PRLDNASDAQ
Prelude Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:PRLD
Prelude Therapeutics (PRLD) is scheduled to report Q3 earnings on November 11, 2026. Analysts estimate EPS of $-0.17 and quarterly revenue of $33.33M.
In the most recent quarter (Q2), Prelude Therapeutics reported EPS of $-0.14, beating estimates of $-0.18 by 0.22%. Revenue came in at $5.7M, exceeding the estimate of $0 by 0%.
Prelude Therapeutics has beaten EPS estimates in 8 consecutive quarters.
Over the last 4 quarters, Prelude Therapeutics has averaged an EPS surprise of 0.29% and a revenue surprise of 0.72%.
Earnings Date
Nov 11
EPS Estimate
$-0.170
Quarterly Revenue Estimate
$33.33M
Annual Revenue
$22.42M
as of Jun 30
Prelude Therapeutics Earnings History
Analyze the earnings history of Prelude Therapeutics using advanced sorting and filters.
Prelude Therapeutics (PRLD) Earnings Per Share
The chart below shows Prelude Therapeutics's reported EPS compared to analyst estimates over recent quarters.
Prelude Therapeutics (PRLD) Revenue
The chart below shows Prelude Therapeutics's reported revenue compared to analyst estimates over recent quarters.
FAQ
When is Prelude Therapeutics (NASDAQ:PRLD) reporting earnings?
Prelude Therapeutics (PRLD) is scheduled to report earnings on November 11, 2026. The last reported earnings were for reported on August 11, 2026 for Q2.
What were the latest earnings per share (EPS) for Prelude Therapeutics (NASDAQ:PRLD)?
The Actual EPS was $-0.14, which beat the estimate of $-0.18.
What were Prelude Therapeutics’s (NASDAQ:PRLD) revenues?
The Actual Revenue was $5.7M, which beat the estimate of $0.
